Philip Morris International, an American-Swiss multinational cigarette and tobacco manufacturing company, agreed to acquire Fertin Pharma, a developer and manufacturer of innovative pharmaceutical and well-being products, from private equity firm EQT Partners and investment company Bagger-Sorensen for $820m. "Fertin Pharma has been on a fantastic journey with EQT and the Bagger-Sørensen family as owners. With the new ownership in place, Fertin Pharma will be in a great position to continue delivering on our vision and mission, including our work as a CDMO for our customers. PMI is going through an inspiring transformation as a company with an ambition to deliver a smoke-free future and building a beyond nicotine product portfolio. An ambition that perfectly matches that of Fertin Pharma, namely to enable people to live healthier lives. In PMI we have found a new owner and partner who shares our vision, who is committed to science and who will enable Fertin Pharma to further accelerate and grow as a company," Peter Halling, Fertin Pharma CEO.